CXCL12 and neoplasm: Suppression of FH2 activity alone via treatment with the FH2 inhibitor SMIFH2, which targets both mDia1 and mDia2 FH2 activity [41], was sufficient to drive amoeboid transition and blebbing in the absence of CXCL12 (Figure 6G), consistent with findings in other tumor cells [41].